Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma

Tianyi Zhang; Yanxian Ren; Pengfei Yang; Jufang Wang; Heng Zhou

doi:10.1038/s41419-022-05351-1

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma

Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

66 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from tumour cells reduce the efficacy of conventional cancer treatment paradigms and contribute to tumour progression and metastasis. As abundant tumour-promoting cells in the ECM, cancer-associated fibroblasts (CAFs) are promising targets for novel anti-tumour interventions. Nonetheless, related clinical trials are hampered by the lack of specific markers and elusive differences between CAF subtypes. Here, we review the origins and functional diversity of CAFs and show how they create a tumour-promoting milieu, focusing on the crosstalk between CAFs, tumour cells, and immune cells in the tumour microenvironment. Furthermore, relevant clinical advances and potential therapeutic strategies relating to CAFs are discussed.

Original language	English
Article number	897
Journal	Cell Death and Disease
Volume	13
Issue number	10
DOIs	https://doi.org/10.1038/s41419-022-05351-1
Publication status	Published - Oct 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41419-022-05351-1

Cite this

@article{63d4bb95c35943cba53da61154c56a82,

title = "Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from tumour cells reduce the efficacy of conventional cancer treatment paradigms and contribute to tumour progression and metastasis. As abundant tumour-promoting cells in the ECM, cancer-associated fibroblasts (CAFs) are promising targets for novel anti-tumour interventions. Nonetheless, related clinical trials are hampered by the lack of specific markers and elusive differences between CAF subtypes. Here, we review the origins and functional diversity of CAFs and show how they create a tumour-promoting milieu, focusing on the crosstalk between CAFs, tumour cells, and immune cells in the tumour microenvironment. Furthermore, relevant clinical advances and potential therapeutic strategies relating to CAFs are discussed.",

author = "Tianyi Zhang and Yanxian Ren and Pengfei Yang and Jufang Wang and Heng Zhou",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = oct,

doi = "10.1038/s41419-022-05351-1",

language = "English",

volume = "13",

journal = "Cell Death and Disease",

issn = "2041-4889",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma

AU - Zhang, Tianyi

AU - Ren, Yanxian

AU - Yang, Pengfei

AU - Wang, Jufang

AU - Zhou, Heng

PY - 2022/10

Y1 - 2022/10

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from tumour cells reduce the efficacy of conventional cancer treatment paradigms and contribute to tumour progression and metastasis. As abundant tumour-promoting cells in the ECM, cancer-associated fibroblasts (CAFs) are promising targets for novel anti-tumour interventions. Nonetheless, related clinical trials are hampered by the lack of specific markers and elusive differences between CAF subtypes. Here, we review the origins and functional diversity of CAFs and show how they create a tumour-promoting milieu, focusing on the crosstalk between CAFs, tumour cells, and immune cells in the tumour microenvironment. Furthermore, relevant clinical advances and potential therapeutic strategies relating to CAFs are discussed.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a prominent extracellular matrix (ECM) deposition and poor prognosis. High levels of ECM proteins derived from tumour cells reduce the efficacy of conventional cancer treatment paradigms and contribute to tumour progression and metastasis. As abundant tumour-promoting cells in the ECM, cancer-associated fibroblasts (CAFs) are promising targets for novel anti-tumour interventions. Nonetheless, related clinical trials are hampered by the lack of specific markers and elusive differences between CAF subtypes. Here, we review the origins and functional diversity of CAFs and show how they create a tumour-promoting milieu, focusing on the crosstalk between CAFs, tumour cells, and immune cells in the tumour microenvironment. Furthermore, relevant clinical advances and potential therapeutic strategies relating to CAFs are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85140616751&partnerID=8YFLogxK

U2 - 10.1038/s41419-022-05351-1

DO - 10.1038/s41419-022-05351-1

M3 - Review article

C2 - 36284087

AN - SCOPUS:85140616751

SN - 2041-4889

VL - 13

JO - Cell Death and Disease

JF - Cell Death and Disease

IS - 10

M1 - 897

ER -

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this